When it comes to breast cancer, the landscape of "prevention" is shifting from a one-size-fits-all approach to highly personalized risk management. The latest National Comprehensive Cancer Network (NCCN) guidelines offer a clear roadmap for staying ahead of the curve.

The Reality in India: 2026 Statistics

The latest data from the Indian Council of Medical Research (ICMR) and recent 2026 reports present a sobering call to action:

•  The Burden: Breast cancer remains the #1 cancer among Indian women, accounting for 27% of all female cancers.

• The Age Gap: Unlike the West, where the median age is 62, Indian women are diagnosed 10–15 years earlier. Approximately 16–20% of new cases are now in women under 40.

• The Survival Challenge: Due to late-stage presentation, the 5-year survival rate in India hovers around 60%, compared to over 90% in high-income countries. This is largely because 57% of cases are diagnosed at Stage III or IV.

• Incidence Hotspots: Cities like Hyderabad (54 per 100,000) and Delhi (41 per 100,000) report rates significantly higher than the national average of 26.6.

Adapting NCCN Standards for Indian Patients

Given the earlier onset of disease in India, the 2026 NCCN recommendation to begin risk stratification at age 25 is particularly critical.

• Customized Screening: For average-risk Indian women, annual screening should begin at age 40. However, for those with a family history, we often recommend starting 10 years earlier than the age of the youngest affected relative.

• The Density Factor: Indian women often have denser breast tissue. I prioritize 3D Mammography (Tomosynthesis) as it reduces the high "false negative" rate common in 2D scans for dense breasts.

Lifestyle & Environmental Factors in India

Recent 2025/26 ICMR studies have identified specific modifiable risks unique to our context:

1. Central Obesity: Elevated waist-to-hip ratios are a significant driver for post-menopausal breast cancer in India.

2. Physical Inactivity: High-intensity movement for 150+ minutes a week has been shown to modulate insulin-like growth factors, a known cancer pathway.

3. Metabolic Health: Irregular sleep patterns and elevated stress levels are now recognized as contributing factors in recent systematic reviews.

A Surgeon's Final Word In India

The greatest barrier to prevention is often social stigma. We must move from "feeling for a lump" to "screening for the invisible." Early detection at Stage I carries a survival rate of nearly 99%. Your lifestyle lowers your baseline risk but your screening schedule should be tailored to your unique genetic and family profile.

Dr Reena Anto Johnson

MBBS, FCPS (General Surgery)

MUHS Breast Fellowship 

Trained at TATA Memorial Hospital

Consultant Breast Surgeon at Renatus Cancer Centre

Within the quiet rhythm of a woman’s body lies a remarkable awareness. Often, the body whispers before it cries out. In the case of Breast Cancer, these whispers can appear as subtle changes—gentle signals asking to be noticed, understood, and addressed. One of the earliest signs may be a new lump or area of thickening in the breast or underarm. It may arrive silently, without pain, and yet it carries significance. While many breast lumps are harmless, a new or persistent one deserves attention and professional evaluation.

Sometimes the signs are seen rather than felt. A breast may change its natural shape or size, or the skin may reveal delicate alterations—dimpling, redness, or a texture resembling the peel of an orange. These changes are the body’s quiet language, asking us to look a little closer. The nipple too may tell a story. A sudden inward turn, unusual discharge, or dryness and scaling around the nipple area may serve as early signals that something beneath the surface requires care. Occasionally, swelling or a small lump in the underarm or near the collarbone may appear, reflecting changes in nearby lymph nodes.

Recognising these signs is only one part of the journey. Medical science also guides us through structured screening and prevention. According to the 2026 recommendations from the National Comprehensive Cancer Network, women at average risk are encouraged to begin annual mammographic screening from the age of 40. Women with higher risk—such as those with strong family histories or genetic predispositions—may benefit from earlier and more comprehensive screening.

Similarly, the American Society of Clinical Oncology and the European Society for Medical Oncology emphasize a thoughtful, risk-based approach to screening and early detection. Their guidance reminds us that vigilance, knowledge, and timely evaluation are powerful allies in protecting women’s health. It is important to remember that breast cancer does not always announce itself loudly in its earliest stages. Often, it begins with the faintest of signals. By learning to recognise these subtle changes, seeking regular screenings, and honoring the body’s messages, women empower themselves with the greatest gift of all—the chance for early detection and timely care. In listening closely to these quiet signs, we do more than observe our health; we safeguard our future.

Dr Reena Anto Johnson

MBBS, FCPS (General Surgery)

MUHS Breast Fellowship 

Trained at TATA Memorial Hospital

Consultant Breast Surgeon at Renatus Cancer Centre

References

1.    National Comprehensive Cancer Network (NCCN). Breast Cancer Screening and Diagnosis
Guidelines (2025-2026 updates).

2.    NCCN Guidelines Insights: Breast Cancer Screening recommendations (annual mammography, risk-based screening).

3.    European Society for Medical Oncology (ESMO). Clinical Practice Guidelines for Breast Cancer (Early and Metastatic).

4.    NCCN Patient Guidelines: Role of screening in detecting cancer before symptoms.

The moment a woman hears the words, “You have a lump in your breast,” her first instinct is often simple and understandable: “Let’s remove it.” After all, if something doesn’t belong, why not take it out immediately?

But in breast surgery, the first step is not always the knife—it is knowledge.

A breast lump is a finding, not a diagnosis. It may be a harmless fibroadenoma that has quietly existed for years, a simple cyst, or an area of benign breast change. Occasionally, it may be breast cancer. While mammography and ultrasound provide valuable clues, they cannot always reveal the complete story. The microscope tells the story that the scan cannot.

Recognising the importance of establishing a diagnosis before treatment, the NCCN Guidelines recommend image-guided core needle biopsy as the preferred method of tissue diagnosis for suspicious breast lesions before definitive surgery. A pre-operative diagnosis allows the multidisciplinary team to plan treatment based not merely on the presence of a lump, but on its biology and behaviour.

A core needle biopsy removes only a few tiny cylinders of tissue, yet those small samples carry answers that shape every treatment decision. They determine whether the lump is benign or malignant, identify the exact tumour type and grade, and, in the case of breast cancer, reveal its hormone receptor (ER/PR) and HER2 status. These findings become the blueprint for personalised treatment.

If the biopsy confirms a benign condition, many women can safely avoid surgery altogether, sparing themselves an unnecessary scar, anaesthesia, recovery, and anxiety. If cancer is diagnosed, the biopsy provides the information needed to choose the right treatment, in the right sequence, for the right patient.

Contrary to popular belief, surgery is not always the first treatment for breast cancer. For many patients—particularly those with HER2-positive or triple-negative breast cancer, or selected patients with larger tumours—chemotherapy and/or targeted therapy before surgery (neoadjuvant therapy) is the recommended approach. This strategy can shrink the tumour, increase the likelihood of breast-conserving surgery, provide valuable insight into the tumour’s response to treatment, and identify patients who may benefit from additional therapies after surgery, ultimately improving long-term outcomes.

Removing a lump without first knowing what it is may seem like the quickest solution, but it can compromise treatment planning. It may lead to positive margins requiring further surgery, inaccurate staging, missed opportunities for neoadjuvant therapy, and less favourable oncological and cosmetic outcomes. The best operation is not necessarily the earliest one, but the right one.

Dr Reena Anto Johnson

MBBS, FCPS (General Surgery)

MUHS Breast Fellowship 

Trained at TATA Memorial Hospital

Consultant Breast Surgeon at Renatus Cancer Centre

Every year, World Breastfeeding Week (1–7 August) celebrates the remarkable benefits of breastfeeding for both mother and child. While breastfeeding is best known for providing ideal nutrition and immunity to infants, it also offers mothers an often-overlooked advantage—a reduced lifetime risk of breast cancer, ovarian cancer and few studies even show for endometrial cancer. At Renatus Cancer Centre, we believe that cancer prevention begins with informed lifestyle choices.

Breast milk is uniquely designed to meet every nutritional need of a growing infant. It contains antibodies, enzymes, hormones, and immune cells that no formula can fully replicate.

For babies, breastfeeding helps:

·         Build a stronger immune system

·         Reduce respiratory and gastrointestinal infections

·         Lower the risk of obesity and type 2 diabetes later in life

·         Support healthy brain development

·         Strengthen emotional bonding with the mother

How Does Breastfeeding Reduce Breast Cancer Risk?

Breastfeeding protects the breast through several biological mechanisms:

·         Reduced estrogen exposure: Breastfeeding delays the return of regular ovulation, reducing lifetime exposure to estrogen, a hormone that can promote the growth of certain breast cancers.

·         Maturation of breast cells: Pregnancy and lactation help breast cells mature, making them less vulnerable to cancer-causing changes.

·         Natural breast remodeling: After breastfeeding ends, the breast undergoes a process that removes older or damaged cells, potentially eliminating cells that could later become cancerous.

·         Healthier metabolism: Breastfeeding is associated with improved weight control and metabolic health, both of which contribute to lower cancer risk.

Current NCCN Breast Cancer Risk Reduction recommendations emphasize:

·         Maintaining a healthy body weight

·         Regular physical activity

·         Limiting alcohol consumption

·         Avoiding tobacco

·         Encouraging breastfeeding whenever possible

While breastfeeding does not eliminate the possibility of breast cancer, it contributes meaningfully to lowering lifetime risk and complements other evidence-based preventive strategies.

How Long Should Mothers Breastfeed?

The World Health Organization (WHO) recommends:

·         Exclusive breastfeeding for the first 6 months

·         Continued breastfeeding along with complementary foods until 2 years of age or beyond, as desired by mother and child

Not every mother is able to breastfeed, and no woman should feel guilty if medical or personal circumstances make breastfeeding difficult. However, for mothers who can, breastfeeding is a natural investment in both their baby’s health and their own future.

This World Breastfeeding Week, let us celebrate breastfeeding not only as the best start for every child but also as a simple, evidence-based step towards reducing breast cancer risk. Combined with a healthy lifestyle, breast awareness, and timely screening, breastfeeding remains an important pillar of lifelong breast health.

References

1)        Stordal B. Breastfeeding reduces the risk of breast cancer: A call for action in high‐income countries with low rates of breastfeeding. Cancer medicine. 2023 Feb;12(4):4616-25.

2)        Babic A, Sasamoto N, Rosner BA, Tworoger SS, Jordan SJ, Risch HA, Harris HR, Rossing MA, Doherty JA, Fortner RT, Chang-Claude J. Association between breastfeeding and ovarian cancer risk. JAMA oncology. 2020 Jun;6(6):e200421.

3)        NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®️): Breast Cancer Risk Reduction. Version 2026.

Dr Reena Anto Johnson

MBBS, FCPS (General Surgery)

MUHS Breast Fellowship 

Trained at TATA Memorial Hospital

Consultant Breast Surgeon at Renatus Cancer Centre